Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 31, 2020

SELL
$5.17 - $8.91 $102,872 - $177,291
-19,898 Closed
0 $0
Q1 2019

Apr 22, 2019

SELL
$9.5 - $19.16 $464,122 - $936,061
-48,855 Reduced 71.06%
19,898 $214,000
Q4 2018

Jan 23, 2019

SELL
$12.69 - $18.61 $152,280 - $223,320
-12,000 Reduced 14.86%
68,753 $1.04 Million
Q2 2018

Jul 31, 2018

SELL
$21.38 - $29.68 $529,796 - $735,470
-24,780 Reduced 23.48%
80,753 $2,000
Q1 2018

May 03, 2018

BUY
$21.76 - $34.22 $1.2 Million - $1.89 Million
55,139 Added 109.42%
105,533 $3,000
Q4 2017

Jan 17, 2018

BUY
$19.0 - $23.09 $418,912 - $509,088
22,048 Added 77.78%
50,394 $1.06 Million
Q3 2017

Oct 16, 2017

BUY
$13.53 - $18.17 $383,521 - $515,046
28,346
28,346 $515,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $71.9M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Hamilton Lane Advisors LLC Portfolio

Follow Hamilton Lane Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hamilton Lane Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hamilton Lane Advisors LLC with notifications on news.